These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34896887)

  • 21. Differences in muscle magnetic resonance imaging findings between anti-signal recognition particle antibody-positive myopathy and anti-aminoacyl-tRNA synthetase antibody-positive myositis.
    Kimura M; Aizawa A; Kudou R; Rikitake Y; Iwao C; Rikitake M; Iwao K; Kariya Y; Kawaguchi T; Matsuda M; Miyauchi S; Takajo I; Umekita K
    Clin Exp Rheumatol; 2024 Feb; 42(2):321-328. PubMed ID: 37497714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autoantibodies and their clinical significance in idiopathic inflammatory myopathies; polymyositis/dermatomyositis and related conditions.
    Hirakata M
    Nihon Rinsho Meneki Gakkai Kaishi; 2007 Dec; 30(6):444-54. PubMed ID: 18174673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis.
    Vojinovic T; Cavazzana I; Ceruti P; Fredi M; Modina D; Berlendis M; Franceschini F
    Clin Rev Allergy Immunol; 2021 Feb; 60(1):87-94. PubMed ID: 33141387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study.
    Ghillani P; André C; Toly C; Rouquette AM; Bengoufa D; Nicaise P; Goulvestre C; Gleizes A; Dragon-Durey MA; Alyanakian MA; Chretien P; Chollet-Martin S; Musset L; Weill B; Johanet C
    Autoimmun Rev; 2011 Jul; 10(9):509-13. PubMed ID: 21447407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune cell profiles of idiopathic inflammatory myopathy patients expressed anti-aminoacyl tRNA synthetase or anti-melanoma differentiation-associated gene 5 autoantibodies.
    Lan JL; Chang SH; Tsay GJ; Chen DY; Chao YH; Li JP
    BMC Immunol; 2023 Sep; 24(1):33. PubMed ID: 37752437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody.
    Sclafani A; D'Silva KM; Little BP; Miloslavsky EM; Locascio JJ; Sharma A; Montesi SB
    Respir Res; 2019 Nov; 20(1):256. PubMed ID: 31718649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics of idiopathic inflammatory myopathies with novel myositis-specific autoantibodies.
    Rams A; Kosałka-Węgiel J; Kuszmiersz P; Matyja-Bednarczyk A; Polański S; Zaręba L; Bazan-Socha S
    Adv Clin Exp Med; 2021 Dec; 30(12):1239-1248. PubMed ID: 34610217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Classification of idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific antibodies].
    Zheng S; Chen S; Wu L; Zhao D; Chen F; Zhu J; Li J
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Jul; 40(7):1029-1035. PubMed ID: 32895158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases.
    Robbins A; Hentzien M; Toquet S; Didier K; Servettaz A; Pham BN; Giusti D
    Front Immunol; 2019; 10():444. PubMed ID: 30915082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoantibodies against the Immunoglobulin-Binding Region of Ro52 Link its Autoantigenicity with Pathogen Neutralization.
    Burbelo PD; Teos LY; Herche JL; Iadarola MJ; Alevizos I
    Sci Rep; 2018 Feb; 8(1):3345. PubMed ID: 29463848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age distribution and prevalence in different age groups of four myositis-specific autoantibodies, including anti-ARS, anti-MDA5, anti-Mi-2, and anti-TIF1γ antibodies.
    Ueda-Hayakawa I; Tonomura K; Maekawa A; Kaneda E; Arase N; Fujimoto M
    J Dermatol; 2023 Aug; 50(8):1058-1062. PubMed ID: 36890683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review.
    Mahler M; Miller FW; Fritzler MJ
    Autoimmun Rev; 2014; 13(4-5):367-71. PubMed ID: 24424190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoantibodies to IgG/HLA class II complexes are associated with rheumatoid arthritis susceptibility.
    Jin H; Arase N; Hirayasu K; Kohyama M; Suenaga T; Saito F; Tanimura K; Matsuoka S; Ebina K; Shi K; Toyama-Sorimachi N; Yasuda S; Horita T; Hiwa R; Takasugi K; Ohmura K; Yoshikawa H; Saito T; Atsumi T; Sasazuki T; Katayama I; Lanier LL; Arase H
    Proc Natl Acad Sci U S A; 2014 Mar; 111(10):3787-92. PubMed ID: 24567378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
    Xu A; Ye Y; Fu Q; Lian X; Chen S; Guo Q; Lu LJ; Dai M; Lv X; Bao C
    Rheumatology (Oxford); 2021 Jul; 60(7):3343-3351. PubMed ID: 33331866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management.
    Decker P; Moulinet T; Pontille F; Cravat M; De Carvalho Bittencourt M; Jaussaud R
    Autoimmun Rev; 2022 Mar; 21(3):103013. PubMed ID: 34896652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical implications of autoantibody screening in patients with autoimmune myositis.
    Ghirardello A; Zampieri S; Tarricone E; Iaccarino L; Bendo R; Briani C; Rondinone R; Sarzi-Puttini P; Todesco S; Doria A
    Autoimmunity; 2006 May; 39(3):217-21. PubMed ID: 16769655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy.
    Rutjes SA; Vree Egberts WT; Jongen P; Van Den Hoogen F; Pruijn GJ; Van Venrooij WJ
    Clin Exp Immunol; 1997 Jul; 109(1):32-40. PubMed ID: 9218821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serological risk factors for concomitant interstitial lung disease in patients with idiopathic inflammatory myopathy.
    Huang HL; Lin WC; Yeh CC; Sun YT
    J Clin Neurosci; 2020 Apr; 74():32-35. PubMed ID: 31982271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latest update on the Ro/SS-A autoantibody system.
    Schulte-Pelkum J; Fritzler M; Mahler M
    Autoimmun Rev; 2009 Jun; 8(7):632-7. PubMed ID: 19393201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.